PLK Inhibitors
Polo-like kinases (PLKs) are a family of highly conserved serine/threonine kinases that serve as master regulators of the cell cycle, particularly during mitosis. Among the five known human PLKs (PLK1-5), PLK1 is the most extensively studied and is considered a prime target for cancer therapy. PLK1 orchestrates several critical stages of mitosis, including centrosome maturation, spindle assembly, the activation of the Anaphase-Promoting Complex/Cyclosome (APC/C), and the execution of cytokinesis. The signaling pathway of PLK1 is characterized by its unique structure, featuring an N-terminal catalytic kinase domain and a C-terminal Polo-box domain (PBD). The PBD is essential for the spatial and temporal localization of the kinase, as it binds to specific phosphoserine or phosphothreonine motifs on its substrates.
Overexpression of PLK1 is a common feature in a variety of human cancers, including acute myeloid leukemia (AML), breast cancer, and non-small cell lung cancer, and is often associated with poor prognosis. Consequently, PLK inhibitors have been developed to induce mitotic arrest and subsequent apoptosis in rapidly dividing tumor cells. These inhibitors are generally classified into two main categories: ATP-competitive small molecules that target the catalytic kinase domain and PBD inhibitors that disrupt the protein-protein interactions required for proper localization. Volasertib (BI 6727) is one of the most advanced ATP-competitive PLK inhibitors and was granted Breakthrough Therapy designation by the FDA for the treatment of AML, although its clinical progress has faced challenges in Phase III trials due to toxicity concerns. Other inhibitors like BI 2536 and Onalespib have also been evaluated in clinical settings.
PBD inhibitors, such as Poloxin, represent a more recent and potentially more selective approach, as the PBD is unique to the PLK family, potentially reducing off-target effects compared to ATP-competitive agents. A significant challenge in the development of PLK inhibitors is the management of hematological toxicities, such as neutropenia and thrombocytopenia, which are common dose-limiting factors. Furthermore, the potential for resistance through the upregulation of alternative mitotic kinases or mutations in the binding pocket remains a concern. Current research is exploring the use of PLK inhibitors in combination with other agents, such as microtubule-stabilizing drugs or DNA-damaging chemotherapies, to enhance therapeutic efficacy. Additionally, the role of other PLK family members, such as PLK4 in centrosome duplication, is being investigated as a target for specific cancer types characterized by centrosome amplification.
As the understanding of PLK biology deepens, the development of next-generation inhibitors with improved selectivity and the identification of predictive biomarkers will be essential for the successful clinical implementation of PLK-targeted therapies.
